Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Recurrence of gout
Systematic review	People with preliminary ACR criteria for gout and serum uric acid ≥ 8.0 mg/dL Data from 1 RCT	Incidence of gout flares at 24 weeks 26/659 (3.9%) with febuxostat 40 mg 27/665 (4.1%) with allopurinol	RR 0.97 95% CI 0.57 to 1.65		Not significant
Systematic review	People with preliminary ACR criteria for gout and serum uric acid 8.0 mg/dL or higher 3 RCTs in this analysis	Incidence of gout flares at 8, 24, or 52 weeks 260/1158 (22%) with febuxostat 80 mg 238/1167 (20%) with allopurinol	RR 1.12 95% CI 0.98 to 1.27		Not significant
Systematic review	People with preliminary ACR criteria for gout and serum uric acid 8.0 mg/dL or higher 2 RCTs in this analysis	Incidence of gout flares at 8 weeks or 52 weeks 247/484 (51%) with febuxostat 120 mg 211/502 (42%) with allopurinol	RR 1.29 95% CI 0.87 to 1.91		Not significant
Systematic review	People with preliminary ACR criteria for gout and serum uric acid 8.0 mg/dL or higher Data from 1 RCT	Incidence of gout flares at 28 weeks 69/134 (52%) with febuxostat 240 mg 61/268 (23%) with allopurinol	RR 2.26 95% CI 1.72 to 2.98	Moderate effect size	allopurinol